orlistat
CLINICAL USE
Adjunct in obesity
DOSE IN NORMAL RENAL FUNCTION
120 mg taken immediately before, during or up to 1 hour after each meal; maximum 360 mg daily
PHARMACOKINETICS
Molecular weight                           :495.7 %Protein binding                           :>99 %Excreted unchanged in urine     : 0–4 Volume of distribution (L/kg)       :No datahalf-life – normal/ESRD (hrs)      :1–2/unchanged DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in normal renal function HD                     :Unlikely to be dialysed. Dose as in normal renal functionHDF/high flux   :Unlikely to be dialysed. Dose as in normal renal functionCAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAcarbose: avoid concomitant administrationAnticoagulants: monitor INR more frequentlyCiclosporin: possibly reduces absorption of ciclosporinVitamins: may reduce the absorption of fat soluble vitamins ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
If the meal doesn’t contain any fat, omit orlistatOrlistat is poorly absorbed; bioavailability of less than 5%.
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home